Gilead Sciences (GILD) Competitors $94.33 +0.31 (+0.33%) (As of 11:58 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GILD vs. AMGN, VRTX, REGN, ALNY, BIIB, UTHR, INCY, NBIX, BMRN, and EXASShould you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Gilead Sciences vs. Amgen Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Is GILD or AMGN more profitable? Amgen has a net margin of 13.00% compared to Gilead Sciences' net margin of 0.45%. Amgen's return on equity of 168.35% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences0.45% 29.00% 9.83% Amgen 13.00%168.35%11.18% Do analysts recommend GILD or AMGN? Gilead Sciences currently has a consensus price target of $95.41, indicating a potential upside of 1.36%. Amgen has a consensus price target of $323.05, indicating a potential upside of 16.00%. Given Amgen's higher possible upside, analysts plainly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 12 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 2.65Amgen 1 Sell rating(s) 13 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.46 Do insiders & institutionals have more ownership in GILD or AMGN? 83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, GILD or AMGN? Gilead Sciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Which has higher earnings & valuation, GILD or AMGN? Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$27.12B4.33$5.67B$0.091,045.89Amgen$28.19B5.31$6.72B$7.8135.66 Does the MarketBeat Community believe in GILD or AMGN? Gilead Sciences received 923 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.90% of users gave Gilead Sciences an outperform vote while only 72.12% of users gave Amgen an outperform vote. CompanyUnderperformOutperformGilead SciencesOutperform Votes246776.90% Underperform Votes74123.10% AmgenOutperform Votes154472.12% Underperform Votes59727.88% Does the media favor GILD or AMGN? In the previous week, Amgen had 46 more articles in the media than Gilead Sciences. MarketBeat recorded 87 mentions for Amgen and 41 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.14 beat Amgen's score of 0.29 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 28 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 32 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 21 Negative mention(s) 3 Very Negative mention(s) Neutral Is GILD or AMGN a better dividend stock? Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 3.3%. Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 3,422.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 115.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 13 consecutive years. SummaryAmgen beats Gilead Sciences on 13 of the 21 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GILD vs. The Competition Export to ExcelMetricGilead SciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$117.31B$3.09B$5.20B$8.97BDividend Yield3.33%1.84%5.23%4.04%P/E Ratio1,045.8915.2685.7113.39Price / Sales4.33315.091,469.4286.49Price / Cash10.35175.8435.2935.09Price / Book5.154.044.914.96Net Income$5.67B-$41.68M$117.36M$224.10M7 Day Performance3.04%6.57%2.75%2.01%1 Month Performance5.16%5.81%1.71%9.79%1 Year Performance21.22%38.20%36.01%29.97% Gilead Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GILDGilead Sciences4.6758 of 5 stars$94.33+0.3%$95.41+1.1%+21.1%$117.56B$27.12B1,048.1118,000Positive NewsAMGNAmgen4.794 of 5 stars$282.87+1.0%$323.05+14.2%+2.1%$152.05B$28.19B36.2226,700Short Interest ↑Analyst RevisionVRTXVertex Pharmaceuticals4.2765 of 5 stars$466.10-0.4%$504.38+8.2%+32.6%$120.03B$9.87B0.005,400Positive NewsREGNRegeneron Pharmaceuticals4.8636 of 5 stars$758.39+1.1%$1,107.29+46.0%-6.4%$83.34B$13.12B18.5713,450Positive NewsALNYAlnylam Pharmaceuticals4.2156 of 5 stars$253.94+0.3%$298.09+17.4%+47.6%$32.75B$1.83B-97.312,100Upcoming EarningsBIIBBiogen4.9564 of 5 stars$160.63+0.5%$257.20+60.1%-30.0%$23.41B$9.84B14.517,570Short Interest ↓Positive NewsUTHRUnited Therapeutics4.6414 of 5 stars$370.62+0.0%$370.86+0.1%+53.7%$16.55B$2.33B16.271,168Positive NewsINCYIncyte4.6683 of 5 stars$73.25-1.8%$77.16+5.3%+35.6%$14.11B$3.70B532.822,524Short Interest ↓NBIXNeurocrine Biosciences4.9227 of 5 stars$126.75+0.1%$163.91+29.3%+7.5%$12.83B$1.89B33.981,400Positive NewsBMRNBioMarin Pharmaceutical4.993 of 5 stars$65.73-0.5%$94.20+43.3%-29.6%$12.53B$2.42B39.543,401Positive NewsEXASExact Sciences4.5416 of 5 stars$60.74-2.2%$75.29+24.0%-8.0%$11.24B$2.50B-53.066,600 Related Companies and Tools Related Companies AMGN Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors BMRN Competitors EXAS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GILD) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GILD Stock Alerts